Windtree Therapeutics Quarterly Income Statements Chart
Quarterly
|
Annual
Windtree Therapeutics Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2012-12-31 | 2011-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| expenses: | |||||||||||||||||||||||||||||
| research and development | 2,253,000 | 3,053,000 | 2,110,000 | 1,763,000 | 1,415,000 | 1,216,000 | 1,543,000 | 2,995,000 | 5,345,000 | 4,476,000 | 4,680,000 | 4,221,000 | 4,410,000 | 3,535,000 | 3,882,000 | 4,495,000 | 3,461,000 | 2,140,000 | 3,792,000 | 3,413,000 | 3,342,000 | 2,368,000 | 2,197,000 | 2,879,000 | 3,118,000 | 2,418,000 | 3,062,000 | ||
| general and administrative | 2,152,000 | 1,906,000 | 2,580,000 | 2,420,000 | 2,292,000 | 2,242,000 | 2,653,000 | 2,907,000 | 2,988,000 | 2,966,000 | 3,467,000 | 3,371,000 | 4,669,000 | 3,426,000 | 4,823,000 | 3,453,000 | 3,242,000 | 2,414,000 | 3,395,000 | 3,240,000 | 3,355,000 | 2,787,000 | 1,500,000 | 1,208,000 | 1,926,000 | 1,182,000 | 1,749,000 | ||
| loss on impairment of goodwill | 2,574,000 | 484,000 | 534,000 | 454,000 | 11,636,000 | ||||||||||||||||||||||||
| total operating expenses | 4,405,000 | 4,959,000 | 4,690,000 | 6,757,000 | 4,191,000 | 10,812,000 | 4,650,000 | 17,538,000 | 8,333,000 | 14,692,000 | 8,147,000 | 45,362,000 | 9,079,000 | 6,961,000 | 8,705,000 | 7,948,000 | 6,703,000 | 5,134,250 | 7,187,000 | 6,653,000 | 6,697,000 | ||||||||
| operating income | -4,405,000 | -4,959,000 | -4,690,000 | -6,757,000 | -4,191,000 | -10,812,000 | -4,650,000 | -17,538,000 | -8,333,000 | -14,692,000 | -8,147,000 | -45,362,000 | -9,079,000 | -6,961,000 | -8,705,000 | -7,948,000 | -6,703,000 | -4,554,000 | -7,187,000 | -6,495,000 | -6,657,000 | -4,851,000 | -3,468,000 | -3,036,000 | -4,840,000 | -3,498,000 | -4,794,000 | ||
| yoy | 5.11% | -54.13% | 0.86% | -61.47% | -49.71% | -26.41% | -42.92% | -61.34% | -8.22% | 111.06% | -6.41% | 470.73% | 35.45% | 52.85% | 21.12% | 22.37% | 0.69% | -6.12% | 107.24% | 113.93% | 37.54% | 38.68% | -27.66% | ||||||
| qoq | -11.17% | 5.74% | -30.59% | 61.23% | -61.24% | 132.52% | -73.49% | 110.46% | -43.28% | 80.34% | -82.04% | 399.64% | 30.43% | -20.03% | 9.52% | 18.57% | 47.19% | -36.64% | 10.65% | -2.43% | 37.23% | 39.88% | 14.23% | -37.27% | 38.36% | -27.03% | |||
| operating margin % | |||||||||||||||||||||||||||||
| other income: | |||||||||||||||||||||||||||||
| gain on debt extinguishment | 14,520,000 | ||||||||||||||||||||||||||||
| interest income | 30,000 | 61,000 | 112,000 | 108,000 | 44,000 | 52,000 | 39,000 | 17,000 | 1,000 | 1,000 | 1,000 | 39,000 | 50,000 | 7,000 | 21,000 | 5,000 | 89,000 | 29,000 | 25,000 | 39,000 | 60,000 | 6,000 | 1,000 | 4,000 | 4,000 | 3,000 | 3,000 | ||
| interest expense | -13,000 | -12,000 | -13,000 | -13,000 | -12,000 | -13,000 | -14,000 | -13,000 | -13,000 | -13,000 | -14,000 | -46,000 | -41,000 | -4,000 | -46,000 | -31,000 | -44,000 | -137,000 | -105,000 | -117,000 | -136,000 | -767,000 | -460,000 | -92,000 | -90,000 | 15,000 | -652,000 | ||
| other income | 201,000 | -244,000 | 166,000 | 61,000 | 48,000 | -286,000 | 569,000 | 201,000 | 218,000 | 109,000 | -437,500 | -290,000 | -1,584,000 | 124,000 | -3,055,000 | 141,000 | 136,000 | 196,000 | -85,000 | 72,000 | 414,000 | ||||||||
| total other income | 14,738,000 | -195,000 | 265,000 | 156,000 | 80,000 | -247,000 | 594,000 | 205,000 | 206,000 | 118,000 | -439,000 | -315,000 | -1,610,000 | ||||||||||||||||
| income before income taxes | 10,333,000 | -11,059,000 | -4,056,000 | -17,333,000 | -14,728,000 | -8,213,000 | -45,721,000 | ||||||||||||||||||||||
| income tax expense | -114,000 | ||||||||||||||||||||||||||||
| net income | 10,219,000 | -5,154,000 | -4,425,000 | -6,601,000 | -4,111,000 | -9,692,000 | -4,056,000 | -17,333,000 | -8,127,000 | -13,073,000 | -8,213,000 | -37,389,000 | -8,961,000 | -7,454,000 | -9,020,000 | -9,558,000 | -6,534,000 | -7,375,000 | -7,126,000 | -6,437,000 | -6,537,000 | -9,042,000 | -3,927,000 | -3,052,000 | -4,512,000 | 2,473,000 | -5,443,000 | ||
| yoy | -348.58% | -46.82% | 9.10% | -61.92% | -49.42% | -25.86% | -50.61% | -53.64% | -9.31% | 75.38% | -8.95% | 291.18% | 37.14% | 1.07% | 26.58% | 48.49% | -0.05% | -18.44% | 81.46% | 110.91% | 44.88% | -465.63% | -27.85% | ||||||
| qoq | -298.27% | 16.47% | -32.96% | 60.57% | -57.58% | 138.95% | -76.60% | 113.28% | -37.83% | 59.17% | -78.03% | 317.24% | 20.22% | -17.36% | -5.63% | 46.28% | -11.40% | 3.49% | 10.70% | -1.53% | -27.70% | 130.25% | 28.67% | -32.36% | -282.45% | -145.43% | |||
| net income margin % | |||||||||||||||||||||||||||||
| net income per common share | |||||||||||||||||||||||||||||
| basic and diluted | 21,980 | -740 | -860 | -1,640 | -4,760 | -61,230 | -130 | -590 | -290 | -420 | -310 | -1,420 | -510 | -430 | -540 | -630 | -480 | -220 | -220 | -200 | -200 | -4,530 | -1,040 | -810 | -1,400 | -21,380 | -690 | ||
| weighted-average number of common shares outstanding | |||||||||||||||||||||||||||||
| basic and diluted | 465,000 | 3,876,000 | 5,148,000 | 4,030,000 | 863,000 | 630,000 | 31,135,000 | 29,200,000 | 28,295,000 | 24,760,000 | 26,704,000 | 26,350,000 | 17,695,000 | 15,654,000 | 16,579,000 | 15,091,000 | 13,697,000 | 32,784,000 | 32,189,000 | 32,189,000 | 32,142,000 | 4,493,000 | 3,769,000 | 3,751,000 | 3,227,000 | 1,028,000 | 10,647,000 | ||
| loss on impairment of intangible assets | 7,250,000 | 37,770,000 | |||||||||||||||||||||||||||
| deferred income tax benefit | 1,655,000 | 8,332,000 | |||||||||||||||||||||||||||
| other (expense) | -74,000 | -53,000 | -352,000 | ||||||||||||||||||||||||||
| total other (expense) | -76,750 | -66,000 | -359,000 | ||||||||||||||||||||||||||
| revenues: | |||||||||||||||||||||||||||||
| license revenue with affiliate | 158,000 | 40,000 | 304,000 | 159,000 | 356,000 | 204,000 | |||||||||||||||||||||||
| total revenues | 158,000 | 40,000 | 304,000 | 229,000 | 1,051,000 | 204,000 | |||||||||||||||||||||||
| other income / | |||||||||||||||||||||||||||||
| other income / (expense) | 169,000 | 59,750 | 61,000 | 58,000 | 120,000 | -4,191,000 | -459,000 | -16,000 | 328,000 | 5,971,000 | -649,000 | ||||||||||||||||||
| grant revenue | 70,000 | 695,000 | 17,000 | ||||||||||||||||||||||||||
| total operating expense | 5,155,000 | 3,697,000 | 4,087,000 | 5,044,000 | 3,600,000 | 4,811,000 | |||||||||||||||||||||||
| deemed dividend on series a preferred stock | -319,000 | -1,915,000 | |||||||||||||||||||||||||||
| net income attributable to common shareholders | -23,265,000 | -3,927,000 | -3,052,000 | -4,512,000 | 2,154,000 | -7,358,000 | |||||||||||||||||||||||
| change in fair value of common stock warrant liability |
We provide you with 20 years income statements for Windtree Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Windtree Therapeutics stock. Explore the full financial landscape of Windtree Therapeutics stock with our expertly curated income statements.
The information provided in this report about Windtree Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.